Targeting the immune inhibitory receptor LILRB4 to treat acute myeloid leukemia (AML)

Written By Mollie Rotmensch

Zhang C. et al. Keystone Symposia on Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit, Whistler, BC, Canada. March 10-14, 2019.

Mollie Rotmensch
Previous

Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development
Next

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration